Press release
Chronic Liver Disease Market to Reach USD 23.8 Billion by 2034
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71133
The demand for innovative treatment approaches, early diagnostic solutions, and effective transplantation services is creating significant opportunities for pharmaceutical firms, medical device makers, and healthcare providers. The market outlook for CLD is strong as healthcare systems increase their focus on prevention, treatment, and management.
Market Overview
• Market Size (2024): USD 13.5 billion
• Forecast (2034): USD 23.8 billion
• CAGR (2025-2034): 5.8%
The chronic liver disease market is expected to witness robust growth due to rising prevalence of NAFLD and alcoholic liver disease, the surge in viral hepatitis cases, and increasing adoption of advanced imaging and transplantation technologies. However, high treatment costs and limited access to liver transplantation continue to pose challenges.
Key Highlights:
• Rising prevalence of obesity and diabetes fueling NAFLD.
• Strong adoption of antiviral therapies for hepatitis B and C.
• Growing liver transplantation demand due to cirrhosis and cancer progression.
• Increasing government initiatives for liver health awareness.
• High treatment costs and donor shortages remain barriers.
Segmentation Analysis
By Product:
• Antiviral Drugs
• Corticosteroids
• Immunosuppressants
• Biologics
• Liver Transplantation Solutions
• Others (nutritional and supportive therapies)
By Platform:
• Small Molecules
• Biologics
• Combination Therapies
By Technology:
• Imaging and Diagnostic Technologies
• Biomarker Discovery Platforms
• Drug Development & Clinical Trials
By End Use:
• Hospitals
• Specialty Clinics
• Research Institutes
By Application:
• Alcoholic Liver Disease
• Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)
• Chronic Hepatitis (B and C)
• Cirrhosis
• Liver Cancer Progression Management
• Transplantation
Segmentation Summary:
NAFLD and hepatitis remain the largest application segments, reflecting the global lifestyle and viral risk factors driving CLD. Antiviral drugs and liver transplantation dominate the treatment space, while biologics and targeted therapies are rising as future growth drivers. Hospitals represent the largest end-user group, given the acute management needs of advanced CLD.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71133/chronic-liver-disease-market
Regional Analysis
North America
• Largest market with ~38% share in 2024.
• Driven by high NAFLD prevalence linked to obesity and diabetes.
• Strong adoption of antiviral therapies and liver transplantation procedures.
Europe
• Holds ~28% of global market.
• High government support for liver disease awareness programs.
• Germany, UK, and France lead in adoption of advanced diagnostics and therapies.
Asia-Pacific
• Fastest-growing region with a CAGR of ~7%.
• High prevalence of hepatitis B and C in China and India.
• Expanding healthcare investments and liver transplantation programs.
Middle East & Africa
• Smaller share, but increasing incidence of lifestyle-related liver disease.
• Growing number of specialized hospitals supporting gradual growth.
Latin America
• Brazil and Mexico drive the market, with increasing awareness and adoption of antiviral drugs.
Regional Summary:
North America and Europe remain strongholds of CLD treatment and research, while Asia-Pacific is set to outpace other regions in growth due to viral hepatitis prevalence, urban lifestyle changes, and rapid healthcare investments.
Market Dynamics
Key Growth Drivers:
• Rising global prevalence of obesity, diabetes, and alcohol consumption.
• Strong demand for antiviral drugs for hepatitis.
• Expanding adoption of liver transplantation services.
• Government programs aimed at early detection and liver health.
• Increasing clinical research in NASH and NAFLD therapies.
Key Challenges:
• High cost of treatment and transplantation.
• Limited availability of liver donors.
• Lack of effective therapies for NASH.
• Regional disparities in healthcare infrastructure.
Latest Trends:
• Growing pipeline of NASH-targeted therapies.
• Precision medicine and biomarker-driven treatment approaches.
• AI-based imaging for early detection and monitoring.
• Expansion of minimally invasive surgical procedures for transplantation.
• Collaborations between global pharma companies and regional research centers.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71133
Competitor Analysis
Major Players in the Market:
• Gilead Sciences, Inc.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Bristol Myers Squibb (BMS)
• Dr. Falk Pharma GmbH
• Intercept Pharmaceuticals
• Zydus Lifesciences
• Johnson & Johnson
• Merck & Co., Inc.
Competitive Summary:
The CLD market is moderately competitive, with leading pharmaceutical firms focusing on antiviral drugs, biologics, and the development of NASH-targeted therapies. Intercept and Gilead are actively advancing drug pipelines in NAFLD/NASH, while AbbVie and Novartis lead in biologics and immunotherapy. Strategic collaborations, partnerships with research institutes, and orphan drug designations are shaping competition.
Conclusion
The Chronic Liver Disease Market, valued at USD 13.5 billion in 2024, is forecasted to reach USD 23.8 billion by 2034, at a CAGR of 5.8%. Growth will be fueled by the rising prevalence of lifestyle-related liver conditions, continued need for antiviral treatments, and expanding access to transplantation.
Key Takeaways:
• NAFLD and hepatitis are the leading segments driving global demand.
• Antiviral therapies dominate, while biologics and NASH-targeted drugs represent future growth.
• North America and Europe lead the market, but Asia-Pacific will show the fastest growth.
• Strategic R&D investments, early diagnostics, and improved patient awareness are critical to future opportunities.
The next decade is expected to transform CLD management through innovation in NASH therapies, precision diagnostics, and transplantation support, making it one of the most dynamic areas of hepatology.
This report is also available in the following languages : Japanese (慢性肝疾患市場), Korean (만성 간 질환 시장), Chinese (慢性肝病市场), French (Marché des maladies chroniques du foie), German (Markt für chronische Lebererkrankungen), and Italian (Mercato delle malattie epatiche croniche), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71133/chronic-liver-disease-market#request-a-sample
Our More Reports:
Leukocyte Adhesion Deficiency Market
https://exactitudeconsultancy.com/reports/71323/leukocyte-adhesion-deficiency-market
Myasthenia Gravis Market
https://exactitudeconsultancy.com/reports/71325/myasthenia-gravis-market
Psoriasis Market
https://exactitudeconsultancy.com/reports/71327/psoriasis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Liver Disease Market to Reach USD 23.8 Billion by 2034 here
News-ID: 4159653 • Views: …
More Releases from Exactitude Consultancy
Autoimmune Hepatitis Market to Hit USD 1.92 Billion by 2034
Autoimmune Hepatitis (AIH) is a rare but serious chronic liver disease caused by the immune system attacking liver cells, leading to inflammation, fibrosis, and potential progression to cirrhosis and liver failure. Though its exact cause is not fully understood, AIH has strong associations with genetic predispositions and environmental triggers. If left untreated, the disease can be fatal, but with timely intervention-primarily corticosteroids and immunosuppressants-long-term survival is possible.
Download Full PDF Sample…
Acute Liver Failure Market Projected to Reach USD 4.3 Billion by 2034
Acute Liver Failure (ALF) is a life-threatening, rapid onset condition wherein sudden liver dysfunction can lead to complications like encephalopathy, coagulopathy, and multi-organ failure. With causes ranging from drug-induced liver injury (notably acetaminophen overdose) to viral hepatitis or autoimmune triggers, ALF demands advanced critical care and often urgent intervention-including liver transplantation. While rare, its acute severity places it at the forefront of hepatology innovation. Rising awareness, diagnostic improvements, and the…
Primary Sclerosing Cholangitis Market to Reach USD 2.5 Billion by 2034
Primary Sclerosing Cholangitis (PSC) is a rare, chronic, progressive liver disease characterized by inflammation and scarring of the bile ducts, which ultimately leads to cirrhosis, liver failure, and, in many cases, the need for liver transplantation. Although the exact cause remains unclear, PSC has strong associations with autoimmune disorders and inflammatory bowel disease (IBD). The growing global prevalence of liver disorders, improved diagnostic techniques, and increased research into rare diseases…
Erosive Esophagitis Market Massive Growth opportunity Ahead
Introduction
Erosive esophagitis (EE) is a severe form of gastroesophageal reflux disease (GERD) characterized by inflammation, erosion, and ulceration of the esophageal lining due to prolonged acid exposure. Symptoms include heartburn, chest pain, dysphagia, and in advanced cases, bleeding and strictures. The condition is widespread, particularly in developed regions, and continues to rise in prevalence due to poor lifestyle habits, obesity, and dietary changes.
While proton pump inhibitors (PPIs) remain the mainstay…
More Releases for Liver
Acute on Chronic Liver Failure Market Impacts Liver Disease Patients By 2031
Global Acute On Chronic Liver Failure Market reached at a CAGR during the forecast period 2024-2031.
Acute On Chronic Liver Failure Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models, financial outcomes, and growth strategies. It serves as a concise yet insightful…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
